Skip to main navigation
Join Our Team
Contact Us
Company
Our Purpose
Company History
Leadership Team
Board
of
Directors
Partnership Opportunities
Corporate Compliance
Exhalation
Delivery Systems
Liquid Delivery
Powder Delivery Device
Anatomy
of the
Nasal Passages
Nasal Delivery Challenges
Therapeutic
Areas
Products
XHANCE
®
ONZETRA
®
Xsail
®
Research &
Development
XHANCE
®
- Future Development
Partnerships
Investors
News & Events
Stock Information
Corporate Governance
SEC Filings
Proxy Materials
Investor Resources
News &
Media
Scientific
Communications
Peer-Reviewed Journal Publications
Presentations
Presentations
Date
Title
11/12/24
Optinose Q3 2024 Earnings
990.7 KB
Investors
News & Events
News Releases
Event Calendar
Presentations
Stock Information
Corporate Governance
SEC Filings
Proxy Materials
Investor Resources
Toolkit
Print page
Sign up for email alerts
Investor Contact
Jonathan Neely
VP Investor Relations and Business Operations
Email:
investors@optinose.com
